Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 44Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms 1Neoadjuvant Therapy 1Low Risk Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Castration Levels of Testosterone 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Abiraterone Acetate 5enzalutamide 4abiraterone 3Prednisone 3apalutamide 2Nivolumab 2Docetaxel 2pembrolizumab 1niraparib 1darolutamide 1cabazitaxel 1Pluvicto 1Omeprazole 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms, Castration-Resistant × apalutamide × Clear all
NCT03173859 2020-11-18

AERA

University of Athens

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02906605 2016-11-22

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Janssen Research & Development, LLC

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡